乳癌名医：饶坤铭　　　　　　　　　　à文章分享 (请点阅) 

现职： 长庚纪念医院高雄分院 血液肿瘤科主任

学经历 :

1994-中山医学院医学系毕业

1994-1997高雄长庚医院内科住院医师

1997-1998林口长庚医院肿瘤内科第一年研究员

1998-1999高雄长庚医院肿瘤内科第二年研究员

1999-至今 高雄长庚医院血液肿瘤科主治医师

2002-2004 美国德州大学M.D. Anderson Cancer Center 癌症分子暨细胞学系(Molecular and Cellular Oncology Department)进修

2005- 长庚大学第二医学研究所硕士班

2005.7-2007.12 高雄长庚医院癌症防治中心负责人

2005.7- 高雄长庚医院血液肿瘤科主任

2008.1- 高雄长庚医院癌症中心运行秘书

教职：

2005-2006义守大学护理学系兼任讲师

2006- 正修科技大学助理教授

20007 长庚医院讲师级主治医师

临床专长

1. 恶性肿瘤诊断

2. 癌症治疗计划之拟定

3. 癌症之全身性治疗 ,包含化学治疗, 标靶治疗, 贺尔蒙治疗

4. 癌症相关症状之处理

5. 专长癌症 : 乳癌, 肺癌, 肠胃道癌症, 肝癌等

专科执照

1. 中华民国内科专科医师

2. 中华民国肿瘤内科专科医师

3. 中华民国乳房专科医师

期刊论文

1. Successful surgical treatment of solitary adrenal metastases from non-small cell lung cancer: case report. Rau KM , Liaw CC, Chang CK, Lee KF. Changgeng Yi Xue Za Zhi. 1999 Jun;22(2):282-6.

2. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC. Cancer Gene Ther. 2004 Nov;11(11):740-7.

3. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. Chen JS, Huang JS, Yang TS, Lin YC, Wang HM, Liau CT, Rau KM. Anticancer Drugs. 2005 Jan;16(1):47-51.

4. The Mechanisms and Managements of Hormone-Therapy Resistance in breast and prostate cancer. Kun-Ming Rau* , Hong-Yo Kang*, Tai-Lung Cha , Stephanie A Miller and Mien-Chie Hung

Endocrine-related Cancer (Sep.1, 2005)

^* Equally contribution

5. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Li SH , Chen WH , Tang Y , Rau KM , Chen YY , Huang TL , Liu JS , Huang CH . Clin Neurol Neurosurg. 2006 Feb;108(2):150-6. Epub 2005 Apr 25.

6. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Rau KM ^* , Day CP ^*, Qiu L , Liu CW , Kuo HP , Xie X , Lopez-Berestein G , Hortobagyi GN , Hung MC . Cancer Gene Ther. 2006 Mar 3;

^* Equally contribution

7. Extrapulmonary small cell carcinoma--a medical center's experience.

Huang TL, Huang CH, Tang Y, Rau KM, Chen YY.

Chang Gung Med J. 2006 Nov-Dec;29(6):590-5

8. Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: no significant correlations with clinicopathological variables and treatment outcomes. Fang FM, Li CF, Chien CY, Rau KM , Huang HY. Int J Pediatr Otorhinolaryngol . 2007 Mar; 71 ( 3 ): 447-55 .

专书及专书论文

1. Duen-Hwa Yan, Kun-Ming Rau, Mien-Chie Hung. 2004 Sep.. Chap. 19 Antimetastasis. Cancer Gene Therapy pp287-298 . Edited by D.T.Curied and J.T. Douglas, Humana Press Inc., Totowa, NJ, USA

2. Kun-Ming Rau, Chi-ping Day, Mien-Chie Hung. Chapter 34 Breast Cancer Gene Therapy. Breast Cancer Management and Molecular Medicine: Towards Tailored Approaches. Edited by M. Piccart. W.C. Wood and M.C.Hung. Springer Berlinh Heiderberg New York

Poster:

1. Selective Breast Tumor Growth Suppression Mediated by the Enhanced Breast Cancer-Specific Promoter

-- 发表于 American Society of Gene Therapy’s 7th Annual Meeting

2. 经肝动脉化学治疗对晚期肝癌病患之疗效

The Therapeutic Effect of Intra-hepatic Arterial Chemotherapy to Advanced Hepatoma

饶坤铭 ¹ 陈彦仰 ¹ 赵景华 ² 郑汝汾 ³

Kun-Ming Rau, M.D. Yeng-Young Chen, M.D.

King-Wah Chiu, M.D. Yu-Fan Cheng, M.D.

临床研究

¨ Phase I, II study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. 共同主持人

¨ Phase II study of pegylated liposomal doxorubicin combined with cyclophosphamide/5-FU as second line chemotherapy in the treatment of metastatic breast cancer ─XMRP 840091 计划主持人

¨ Phase II Study of UFUR in Combination with Gemcitabine and Cisplatin in Patients with Advanced Bladder Cancer. 共同主持人

¨ Phase III study of EPO-alfa as an adjuvant therapy in metastatic breast cancer patients accepting the first line chemotherapy─XMRP 850171 计划主持人

¨ Randomized double blind placebo-controlled trial of pregabilin for cancer pain from bone metastasis─XMRPG860012 计划主持人

¨ Phase II study with weekly Eloxatin and taxotere as the first line therapy for advanced gastric cancer patients─XMRG860171 计划主持人

¨ FOLFOX 4 versus doxorubicin as the palliative chemotherapy for unresectable advanced hepatoma patients─XMRPG 860281 计划主持人

¨ VEGF as a predictive marker to the therapeutic effect of hepatoma intraarterial chemotherapy.─CMRPG 840681 计划主持人

¨ Phase III study of randomized, double blind, placebo-controlled trial o ZD6474 for one tyrosine kinase inhibitor refractory advanced NSCLC patients -- 共同主持人